To examine if EPHB6 supports cancer drug resistance, we treated mice with MDA-pc3 or MDA-B6-M tumours with a DNA-damaging drug, doxorubicin, which is frequently used in TNBC therapy. The gene discussed is EPHB6; the disease is cancer.